Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Accumulated Expenses: 2014-2025

Historic Other Accumulated Expenses for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $341,000.

  • CytomX Therapeutics' Other Accumulated Expenses rose 16.78% to $341,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $341,000, marking a year-over-year increase of 16.78%. This contributed to the annual value of $490,000 for FY2024, which is 56.05% up from last year.
  • CytomX Therapeutics' Other Accumulated Expenses amounted to $341,000 in Q3 2025, which was up 207.21% from $111,000 recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Other Accumulated Expenses peaked at $943,000 during Q1 2022, and registered a low of $63,000 during Q1 2025.
  • For the 3-year period, CytomX Therapeutics' Other Accumulated Expenses averaged around $284,636, with its median value being $314,000 (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 601.52% in 2021, then slumped by 86.15% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Other Accumulated Expenses (Quarterly) stood at $713,000 in 2021, then crashed by 63.39% to $261,000 in 2022, then increased by 20.31% to $314,000 in 2023, then soared by 56.05% to $490,000 in 2024, then increased by 16.78% to $341,000 in 2025.
  • Its last three reported values are $341,000 in Q3 2025, $111,000 for Q2 2025, and $63,000 during Q1 2025.